Department of Anesthesia & Perioperative Medicine, Evidence-Based Perioperative Clinical Outcomes Research Group (EPiCOR), London Health Sciences Centre, The University of Western Ontario, London, Ontario, Canada.
J Am Coll Cardiol. 2010 Mar 9;55(10):986-1001. doi: 10.1016/j.jacc.2009.11.047.
The purpose of this study was to determine whether thoracic endovascular aortic repair (TEVAR) reduces death and morbidity compared with open surgical repair for descending thoracic aortic disease.
The role of TEVAR versus open surgery remains unclear. Metaregression can be used to maximally inform adoption of new technologies by utilizing evidence from existing trials.
Data from comparative studies of TEVAR versus open repair of the descending aorta were combined through meta-analysis. Metaregression was performed to account for baseline risk factor imbalances, study design, and thoracic pathology. Due to significant heterogeneity, registry data were analyzed separately from comparative studies.
Forty-two nonrandomized studies involving 5,888 patients were included (38 comparative studies, 4 registries). Patient characteristics were balanced except for age, as TEVAR patients were usually older than open surgery patients (p = 0.001). Registry data suggested overall perioperative complications were reduced. In comparative studies, all-cause mortality at 30 days (odds ratio [OR]: 0.44, 95% confidence interval [CI]: 0.33 to 0.59) and paraplegia (OR: 0.42, 95% CI: 0.28 to 0.63) were reduced for TEVAR versus open surgery. In addition, cardiac complications, transfusions, reoperation for bleeding, renal dysfunction, pneumonia, and length of stay were reduced. There was no significant difference in stroke, myocardial infarction, aortic reintervention, and mortality beyond 1 year. Metaregression to adjust for age imbalance, study design, and pathology did not materially change the results.
Current data from nonrandomized studies suggest that TEVAR may reduce early death, paraplegia, renal insufficiency, transfusions, reoperation for bleeding, cardiac complications, pneumonia, and length of stay compared with open surgery. Sustained benefits on survival have not been proven.
本研究旨在确定胸主动脉腔内修复术(TEVAR)与开放手术修复降主动脉疾病相比,是否能降低死亡率和发病率。
TEVAR 与开放手术的作用仍不清楚。荟萃回归可用于通过利用现有试验的证据,最大限度地为新技术的采用提供信息。
通过荟萃分析合并了 TEVAR 与开放修复降主动脉的比较研究的数据。进行荟萃回归以考虑基线风险因素的不平衡、研究设计和胸主动脉病变。由于存在显著的异质性,因此分别从比较研究和登记处数据进行分析。
纳入了 42 项非随机研究共 5888 例患者(38 项比较研究,4 项登记处)。患者特征除年龄外均平衡,TEVAR 患者通常比开放手术患者年龄大(p = 0.001)。登记处数据表明总体围手术期并发症减少。在比较研究中,TEVAR 与开放手术相比,30 天全因死亡率(比值比 [OR]:0.44,95%置信区间 [CI]:0.33 至 0.59)和截瘫(OR:0.42,95% CI:0.28 至 0.63)降低。此外,心脏并发症、输血、出血再手术、肾功能不全、肺炎和住院时间减少。在 1 年以上,中风、心肌梗死、主动脉再干预和死亡率无显著差异。进行荟萃回归以调整年龄不平衡、研究设计和病理学并没有实质性改变结果。
来自非随机研究的现有数据表明,与开放手术相比,TEVAR 可能降低早期死亡率、截瘫、肾功能不全、输血、出血再手术、心脏并发症、肺炎和住院时间。尚未证明生存的持续获益。